Reviva Pharmaceuticals Holdings, Inc.
RVPH
$0.5834
-$0.0166-2.77%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.60M | 2.55M | 2.14M | 1.51M | 1.99M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.46M | 8.13M | 7.92M | 9.99M | 11.56M |
| Operating Income | -8.46M | -8.13M | -7.92M | -9.99M | -11.56M |
| Income Before Tax | -8.37M | -7.85M | -7.43M | -9.73M | -11.33M |
| Income Tax Expenses | -- | 7.40K | 7.40K | -4.60K | 12.10K |
| Earnings from Continuing Operations | -8.37M | -7.86M | -7.43M | -9.72M | -11.35M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.37M | -7.86M | -7.43M | -9.72M | -11.35M |
| EBIT | -8.46M | -8.13M | -7.92M | -9.99M | -11.56M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.25 | -0.26 | -0.25 | -0.36 | -0.48 |
| Normalized Basic EPS | -0.15 | -0.16 | -0.16 | -0.23 | -0.30 |
| EPS Diluted | -0.25 | -0.26 | -0.25 | -0.36 | -0.48 |
| Normalized Diluted EPS | -0.15 | -0.16 | -0.16 | -0.23 | -0.30 |
| Average Basic Shares Outstanding | 33.80M | 30.56M | 29.89M | 26.87M | 23.64M |
| Average Diluted Shares Outstanding | 33.80M | 30.56M | 29.89M | 26.87M | 23.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
